Abstract: Methods for diagnosing, treating, and monitoring the treatment of fusariosis or scedosporiosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having fusariosis or scedosporiosis.

Abstract: A method for manufacturing bacterially induced crystal particle includes culturing bacteria in a culture medium including a carbon source and a raw metal material including a transition metal, so that the bacteria induce a raw metal material to undergo a reduction-oxidation reaction; isolating a wet powder material from the culture medium; and drying the wet powder material to obtain a powder material. The powder material includes at least one bacterially induced crystal particle.

Abstract: Human-derived probiotic strains Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384 and Lactobacillus paracasei KBL385 are described, as well as uses of the strains for improving intestinal health and treating or preventing intestinal diseases. The strains have excellent anti-inflammatory and immunomodulatory functions, superb strengthening effects on tight junctions of the intestinal tract wall, suppress enteritis-induced weight loss and colon length reduction, thereby exhibiting therapeutic effects for enteritis, and significantly alleviate the symptoms of atopic dermatitis. The strains can be used as probiotic material for enhancing anti-inflammatory effects, strengthening immunity, improving intestinal health functions, and alleviating allergic diseases.

Abstract: A method of controlling a bioreactor system includes providing a cell culture in a bioreactor, wherein conditions in the bioreactor enable the cell culture to produce a protein of interest (POI), measuring process parameters (PPs) of the culture within the bioreactor by RAMAN, wherein the process parameters are selected from the group consisting of nutrient concentration, viable cell concentration, and protein attributes, measuring a predetermined weight of the bioreactor with the cell culture, removing cell-free spent media from the cell culture using a first output conduit at a first specified rate, removing cells from the cell culture using a second output conduit at a second specified rate, and introducing one or both of fresh media or nutrients into the cell culture using an input conduit at a third specified rate.

Abstract: The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

Abstract: A device and method for analyte detection and analytes in a particulate bearing fluid such as whole blood having an instrument for partitioning the particles from the fluid that is integrated with a detector for analyzes of one or more particulate bearing fluid analytes while the particles in the particulate bearing fluid are partitioned.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A composition for treating irritable bowel syndrome can include a mixture of Bacillus amyloliquefaciens, Enterococcus faecium, and Vitamin D (Calciferol). The composition can be administered to a patient to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome. For example, the composition can be used to treat colitis. The composition can include about 1×106 to 1×1012 colony forming units (CFU) of Bacillus amyloliquefaciens and Enterococcus faecium per unit dose. In an embodiment, the composition can include at least 1 to 25 mg/L Vitamin-D.

Abstract: The present invention relates to a feed supplement for addition to drinking water, for improved animal health. The feed supplement includes short chain fatty acids, a nitrogenous compound, a source of inositol and a source of xylanase. The feed supplement reduces the need for pharmaceutical inputs and increases both animal health and yield.

Abstract: A composition for treating irritable bowel syndrome can include a mixture of Bacillus amyloliquefaciens, Enterococcus faecium, and Vitamin D (Calciferol). The composition can be administered to a patient to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome. For example, the composition can be used to treat colitis. The composition can include about 1×106 to 1×1012 colony forming units (CFU) of Bacillus amyloliquefaciens and Enterococcus faecium per unit dose. In an embodiment, the composition can include at least 1 to 25 mg/L Vitamin-D.

Abstract: A method of inhibiting oral pathogens comprising administering to a subject in need thereof an effective amount of Lactobacillus strain-containing food composite, medical composite and oral cleaning composite. The food composite, medical composite and oral cleaning composite comprises at least one Lactobacillus strain, which is at least one isolated Lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain, CCTCC NO: M2011124; Lactobacillus salivarius subsp. salicinius AP-32 strain, CCTCC NO: M2011127; Lactobacillus reuteri GL-104 strain, CCTCC NO: M209138; Lactobacillus paracasei GL-156 strain, CCTCC NO: M2014590; Lactobacillus helveticus RE-78 strain, CGMCC No. 13513; Lactobacillus rhamnosus CT-53 strain, CCTCC NO: M2011129; and Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).

Abstract: The present disclosure relates to amoebae (slime molds) and uses thereof. In particular, the present disclosure relates to the use of amoebae or their environmentally stable spores to control agricultural infections and other uses.

Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

Abstract: Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Abstract: An object of the present invention is to provide a novel composition for promoting the secretion of FGF21. The object is achieved by a composition for promoting the secretion of FGF21, including a Bifidobacterium bacterium as an active ingredient.

Abstract: The invention provides a method and related compositions for preparing an effective probiotic bacteria formulation that can be stored, transported and used for protecting a variety of marine organisms against infection by potential pathogens.

Abstract: Prebiotic composition including grape ferment, a first component, and a second component is provided. The first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide, or inulin. The first component is different from the second component, and a weight ratio of the grape ferment, the first component and the second component falls within the range of 1-2:1-2:1-2. Based on this, the prebiotic composition prepared by grape ferment can be used to promote intestinal health of a subject in need thereof and enhance antioxidation in the subject.

Abstract: To determine the presence of Mycobacterium in an environment, a sample from the environment can be plated onto a growth medium that is selective for Mycobacterium. The agar based growth medium can include a high concentration of crystal violet, in excess of 0.5 ?g/ml. The process may be made further selective for Mycobacterium by treating the sample with sodium dodecyl sulfate containing glycine hydrochloride for at least 4 minutes at room temperature, prior to plating. Mycobacterium colonies will generally appear white while other colonies will generally appear stained purple or another color.

Abstract: Disclosed herein is a method for alleviating atopic dermatitis using a composition containing at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the CCTCC under an accession number CCTCC M 2014588.